Drug General Information |
Drug ID |
D03HLH
|
Former ID |
DNC003881
|
Drug Name |
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H13BrN2O3
|
Canonical SMILES |
COC1=C(C=C2C(=C1)C(=NC=N2)OC3=CC(=CC=C3)Br)OC
|
InChI |
1S/C16H13BrN2O3/c1-20-14-7-12-13(8-15(14)21-2)18-9-19-16(12)22-11-5-3-4-10(17)6-11/h3-9H,1-2H3
|
InChIKey |
BRHOGFZRGDIAMT-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
Epidermal growth factor receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
MAPK signaling pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
Cytokine-cytokine receptor interaction
|
PI3K-Akt signaling pathway
|
Focal adhesion
|
Gap junction
|
Regulation of actin cytoskeleton
|
HTLV-I infection
|
Pathways in cancer
|
MicroRNAs in cancer
|
Glioma
|
Prostate cancer
|
Melanoma
|
Central carbon metabolism in cancer
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
ErbB signaling pathway
|
HIF-1 signaling pathway
|
FoxO signaling pathway
|
Endocytosis
|
Dorso-ventral axis formation
|
Adherens junction
|
GnRH signaling pathway
|
Estrogen signaling pathway
|
Oxytocin signaling pathway
|
Epithelial cell signaling in Helicobacter pylori infection
|
Hepatitis C
|
Proteoglycans in cancer
|
Pancreatic cancer
|
Endometrial cancer
|
Bladder cancer
|
Non-small cell lung cancer
|
Choline metabolism in cancer
|
NetPath Pathway
|
IL4 Signaling Pathway
|
EGFR1 Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
PDGF signaling pathwayP00012:Cadherin signaling pathway
|
EGF receptor signaling pathway
|
Pathway Interaction Database
|
Signaling events mediated by PTP1B
|
Beta3 integrin cell surface interactions
|
S1P3 pathway
|
Nectin adhesion pathway
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
PDGFR-beta signaling pathway
|
Validated targets of C-MYC transcriptional repression
|
PDGF receptor signaling networklysophospholipid_pathway:LPA receptor mediated events
|
Arf6 signaling events
|
Thromboxane A2 receptor signaling
|
Regulation of Telomerase
|
EGF receptor (ErbB1) signaling pathway
|
EGFR-dependent Endothelin signaling events
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
ErbB1 downstream signaling
|
E-cadherin signaling in keratinocytes
|
ErbB receptor signaling network
|
Internalization of ErbB1
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
Syndecan-3-mediated signaling events
|
Reactome
|
PIP3 activates AKT signaling
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
RAF/MAP kinase cascadeR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
SHC1 events in ERBB2 signaling
|
PLCG1 events in ERBB2 signaling
|
GRB2 events in EGFR signaling
|
GAB1 signalosome
|
SHC1 events in EGFR signaling
|
EGFR downregulation
|
GRB2 events in ERBB2 signaling
|
PI3K events in ERBB2 signaling
|
EGFR Transactivation by Gastrin
|
Constitutive Signaling by EGFRvIII
|
RAF/MAP kinase cascade
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
MAPK Signaling Pathway
|
Osteoblast Signaling
|
Focal Adhesion
|
PIP3 activates AKT signaling
|
PDGF Pathway
|
Signaling Pathways in Glioblastoma
|
Signaling by PDGFWP673:ErbB Signaling Pathway
|
EGF/EGFR Signaling Pathway
|
Aryl Hydrocarbon Receptor Pathway
|
Extracellular vesicle-mediated signaling in recipient cells
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
Bladder Cancer
|
Hair Follicle Development: Induction (Part 1 of 3)
|
Signaling by ERBB4
|
Signaling by ERBB2
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
Nanoparticle-mediated activation of receptor signaling
|
Aryl Hydrocarbon Receptor
|
Spinal Cord Injury
|
Integrated Pancreatic Cancer Pathway
|
Gastric cancer network 2
|
AGE/RAGE pathway
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Integrated Breast Cancer Pathway
|
Signaling by EGFR
|
L1CAM interactions
|
References |
REF 1 | A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). |